Table 1.

Expression of CD75s-1- and iso-CD75s-1-gangliosides in pancreatic carcinoma tissues

CD75s-1
iso-CD75s-1
Category*%RankGradePatientCategory*% AgeRankGradePatient
I10.51238I7.91238
23242418
34183324
432II57.9421
II31.6526523
62362-38
72117314
83348227
9219330
1032110213
1133511219
1232812322
13X41325
1431514232
1531715329
1623216225
III55.31732917321
1832218315
1921319236
2021920335
213142126
2223122328
2323623210
2433724337
2533025216
2925III21.12629
292-3827231
2921028233
2921629211
2922330317
2932631334
2922732X4
33293332
34225IV13.234212
3521235326
362736220
372333727
IV2.63822038223
  • * Based on the ranking data, tumors were grouped into categories I to IV corresponding to high (I) and moderate (II) overexpression and equal (III) and lowered (IV) expression.

  • The 38 tumors were ranked from 1 to 38, whereby rank 1 indicates the highest, rank 2 the second highest, etc., and rank 38 the lowest expression of CD75s-gangliosides.

  • Histopathologic grading: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated; X, histopathologic grading cannot be assessed.